This article has been updated to note that all high-risk smoldering multiple myeloma patients will develop active disease.
NEW YORK – Researchers at the Multiple Myeloma Research Foundation and Dana Farber Cancer Institute are building a more complete picture of the genomic events that drive some patients with smoldering multiple myeloma to develop active disease, and they will use this knowledge to advance a liquid biopsy test for monitoring patients and identifying those at high-risk of progression.